World Class Bodybuilding   Forum


Join worldclassbodybuilding

Join the #1 Bodybuilding Fitness Forum Today - It's Free!

Welcome to Bodybuilding Discussion Forums - Are you interested in Bodybuilding or Fitness? If so we invite you to join our community and see what it has to offer. Our site is specifically designed for you and it's the leading place for Fitness minded people to meet online. Just fellow bodybuilders and fitness enthusiasts who enjoy talking about their lifestyle, their routines, and just everyday banter. We have Articles, knowledgable members, Questions and Answers that you might not find anywhere else, Steroid and Supplemnent Profiles, Routines, a Supplement Store and a lot more So no matter what your fitness background is, beit new to the fitness world or Professional athlete, you'll find that worldclassbodybuilding .com is a great community to join. Best of all it's free!

Join Worldclassbodybuilding - Click Here JOIN FOR FREE


Go Back   World Class Bodybuilding Forum > Anabolic Steroid Discussion > Anabolic Steroids

WCBB Weekend Shoutbox
Loading...


Anabolic Steroids Up to date Anabolic steroids discussion group and how it relates to bodybuilding and fitness . The most mature and trusted provider of Anabolic Steroids information.


Reply
 
LinkBack Thread Tools Display Modes
  #1  
Old 09-14-2010, 10:40 PM
Worldclassbodybuilder
 
Join Date: Jun 2010
Posts: 33
Thanks: 3
Thanked 1 Time in 1 Post
Rep Power: 50
thepalerider is on a distinguished road
Pramipexole

Could someone tell what Pramipexole is used for mostly. Is is mostly for increasing Libido? What are it's usages or what is it mostly used for. When should you use it and when should you not use it? What are the side effects, if any? Thanks guys
Reply With Quote
Advertisements
Advertise at WCBB
Advertise at WCBB WCBB Is online now
Points: 413,418, Level: 100 Points: 413,418, Level: 100 Points: 413,418, Level: 100
Activity: 100% Activity: 100% Activity: 100%
 
Join Date: Jan 2004
Location: Looking for supplement deals
Posts: 60,683
Thanks: 11,143
Thanked 23,653 Times in 12,344 Posts
WCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond repute

MuscleEgg Liquid Egg Whites
  #2  
Old 09-15-2010, 04:17 AM
DOUBLE J's Avatar
WhoDat
 
Join Date: Jan 2004
Posts: 7,633
Thanks: 8
Thanked 103 Times in 65 Posts
Rep Power: 271
DOUBLE J has a brilliant futureDOUBLE J has a brilliant futureDOUBLE J has a brilliant futureDOUBLE J has a brilliant futureDOUBLE J has a brilliant futureDOUBLE J has a brilliant futureDOUBLE J has a brilliant futureDOUBLE J has a brilliant futureDOUBLE J has a brilliant futureDOUBLE J has a brilliant futureDOUBLE J has a brilliant future
My Pramipexol Log
Reply With Quote
  #3  
Old 09-15-2010, 08:05 PM
N4cer's Avatar
Community Veteran
 
Join Date: Jul 2007
Location: Midwest USA
Posts: 802
Thanks: 67
Thanked 239 Times in 151 Posts
Rep Power: 94
N4cer is on a distinguished road
Pramipexole is an anti-hyperprolactinemic. In other words, its role is to reduce circulatory prolactin. You're misusing the word libido, as so many others do. Prolactin is the hormone that causes men to have a refractory period between orgasms. Reducing prolactin can allow a shorter refractory period in some men, but is by no means an indicator of effect.
Reply With Quote
  #4  
Old 09-24-2010, 09:34 AM
BigBlue's Avatar
Worldclassbodybuilder
 
Join Date: Jun 2010
Posts: 5
Thanks: 0
Thanked 1 Time in 1 Post
Rep Power: 0
BigBlue is on a distinguished road
There's a lot of really good science discussion of Prami in a sticky at AF. I don't normally mention other forums within a forum, but the discussion is so good that I can't resist. Definitely read it over.
Reply With Quote
  #5  
Old 09-29-2010, 03:38 PM
heavyiron's Avatar
Community Veteran
 
Join Date: Sep 2010
Location: staying anabolic
Posts: 30
Thanks: 1
Thanked 13 Times in 11 Posts
Rep Power: 47
heavyiron is on a distinguished road
As mentioned it lowers prolactin and shortens the refractory period between orgasms.

There are various trials showing it increases the desire for sex.

It is a difficult med to get used to becuase of its ability to either make you very sleepy or keep you awake. You must slowly increase the dose and dose multiple times daily with smaller doses or you can have very pronounced side effects. I tried to dial it in for months and finally gave up. I just like to sleep too much to deal with Prami.

I will dig up some studies for you guys...

Last edited by heavyiron; 09-29-2010 at 03:43 PM.
Reply With Quote
  #6  
Old 09-29-2010, 03:40 PM
heavyiron's Avatar
Community Veteran
 
Join Date: Sep 2010
Location: staying anabolic
Posts: 30
Thanks: 1
Thanked 13 Times in 11 Posts
Rep Power: 47
heavyiron is on a distinguished road
Pramipexole lowers prolactin and raises HGH in a dose dependant relationship so the more you take the more it works.



Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans.

Schilling JC, Adamus WS, Palluk R.

Human Pharmacology Centre, Boehringer Ingelheim KG, Germany.

The effects and tolerability of pramipexole, a new dopamine D2-receptor agonist, on prolactin, human growth hormone, thyrotropin, cortisol, and corticotropin levels were investigated in a randomized, double-blind, crossover study in 12 healthy volunteers. Single oral doses of 0.1, 0.2, and 0.3 mg pramipexole and placebo were studied over a period of 24 hours. Pramipexole decreased serum prolactin levels in a dose-dependent manner, with a maximum effect after 2 to 4 hours. Serum levels of human growth hormone were dose-dependently increased; however, this effect was only significant 2 hours after drug administration. Furthermore, a slight increase in serum cortisol levels and a slight decrease in serum thyrotropin levels was observed. Our findings show for the first time pharmacodynamic effects of pramipexole after single oral doses in healthy volunteers. The compound was well tolerated and showed an endocrine profile similar to other dopamine D2-agonists.

PMID: 1350237 [PubMed - indexed for MEDLINE]
Reply With Quote
  #7  
Old 09-29-2010, 03:42 PM
heavyiron's Avatar
Community Veteran
 
Join Date: Sep 2010
Location: staying anabolic
Posts: 30
Thanks: 1
Thanked 13 Times in 11 Posts
Rep Power: 47
heavyiron is on a distinguished road
Prami may encourage freaky behavior in the bedroom and the casino.




Increased frequency and range of sexual behavior in a patient with Parkinson's disease after use of pramipexole: a case report.

Munhoz RP, Fabiani G, Becker N, Teive HA.

Movement Disorders Unit, Neurology Service, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.

INTRODUCTION: Several recent reports have linked the use of dopamine agonists (DAs) to a variety of compulsive behaviors in patients with Parkinson's disease (PD). These inappropriate behaviors may include pathological gambling, compulsive shopping, and hypersexuality. AIM: To report the case of a patient with increased range of sexual behavior after use of pramipexole, a DA. METHODS: A 67-year-old man with a 7-year diagnosis of PD treated with levodopa and pramipexole presented with a dramatic change in sexual behavior after an increase in DA dose. RESULTS: The patient, who historically was a very shy and conservative person, started to present increased frequency of sexual intercourse with his wife, during which he began speaking obscenities with an extreme preference for anal intercourse, preferences never requested before. After pramipexole was withdrawn, complete remission was observed with return to his usual sexual behavior. CONCLUSIONS: Hypersexuality and paraphilias are complications not uncommonly found in patients with PD under dopaminergic treatment. Further studies are needed for the understanding of this complex complication, and particularly the most prevalent relationship between pathological hypersexuality and use of DAs.

PMID: 18466265 [PubMed - indexed for MEDLINE]
Reply With Quote
The Following User Says Thank You to heavyiron For This Useful Post:
basskiller  (09-29-2010)
  #8  
Old 09-29-2010, 03:43 PM
heavyiron's Avatar
Community Veteran
 
Join Date: Sep 2010
Location: staying anabolic
Posts: 30
Thanks: 1
Thanked 13 Times in 11 Posts
Rep Power: 47
heavyiron is on a distinguished road
Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.
Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH.

Department of Neurology, Parkinson's Disease and Movement Disorders Center, Mayo Clinic, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, USA. driverdunckley.erika@mayo.edu

OBJECTIVES: Do patients with restless legs syndrome (RLS) report gambling or other abnormal behaviors as previously reported in Parkinson disease. METHODS: This survey study was sent to 261 idiopathic RLS patients, and it included the Gambling Symptoms Assessment Scale, Altman Self-Rating Mania Scale, and questions pertaining to sexual activity and novelty-seeking behaviors. RESULTS: Ninety-nine patients responded to the survey, and 77 were actively taking 1 or more dopaminergic medications. Of the 70 respondents who answered the gambling questions, 5 (7%) noted a change in gambling, with 4 (6%; 95% confidence interval, 2%-14%) stating that increased urges and time spent gambling occurred specifically after the use of dopaminergic medications (2 on pramipexole, 1 on ropinirole, and 1 on levodopa and pramipexole). Increased sexual desire was reported by 4 (5%) of the 77 respondents, 3 (4%; 95% confidence interval, 1%-11%) reported that this occurred specifically after the use of dopaminergic medications (1 on pramipexole, 1 on ropinirole, and 1 on levodopa). One patient reported both an increase in gambling and sexual habits. CONCLUSIONS: This exploratory survey study revealed the development of gambling and/or increased sexuality in patients with RLS. These data raise the possibility that, as in Parkinson disease, RLS patients should be cautioned about potential behaviors that may occur with the use of dopaminergic medications. Further prospective studies are needed to assess the relationship between these medications and compulsive behaviors associated with the treatment of RLS.

PMID: 17909302 [PubMed - indexed for MEDLINE]
Reply With Quote
The Following User Says Thank You to heavyiron For This Useful Post:
basskiller  (09-29-2010)
  #9  
Old 09-29-2010, 03:45 PM
heavyiron's Avatar
Community Veteran
 
Join Date: Sep 2010
Location: staying anabolic
Posts: 30
Thanks: 1
Thanked 13 Times in 11 Posts
Rep Power: 47
heavyiron is on a distinguished road
Prami reduces depression and allows more feelings of pleasure.


Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.

Lemke MR, Brecht HM, Koester J, Reichmann H.
Center of Psychiatry and Neurology, Rhine Clinic Bonn, Germany. mr.lemke@lvr.de

Depression affects approximately 45% of all patients with Parkinson's disease, reduces quality of live independent of motor symptoms and seems to be underrated and undertreated. Pramipexole shows D(3)- versus D(2)-receptor preference at cortico-frontal dopamine receptors and neurotrophic effects which seem to relate to its antidepressant and anti-anhedonic properties in Parkinson's disease and bipolar depression found in controlled studies. In the present study, effects of pramipexole were investigated under routine clinical conditions. Anhedonia was measured in patients with Parkinson's disease (n=657) using the self-rated Snaith-Hamilton-Pleasure-Scale (SHAPS-D), depression was assessed by the observer-rated Short-Parkinson's-Evaluation Scale (SPES). Anhedonia was present in 45.7% of all patients and in 79.7% of the depressed patients with Parkinson's disease. Mild depression was present in 47%, moderate to severe depression in 22% of the patients. At the end of the study period of 9 weeks on an average, the mean dosage of pramipexole was 1.0+/-0.6 mg/d (range 0.3 to 4.2). Frequency of depression (moderate to severe: 6.8%, mild: 37.6%) and anhedonia (25.5%) as well as motor deficits were significantly reduced during treatment with pramipexole. Drop-outs due to adverse events occurred in 3.5%. Future studies should investigate specificity of anti-anhedonic and antidepressive properties of pramipexole.

PMID: 16814808 [PubMed - indexed for MEDLINE]
Reply With Quote
The Following User Says Thank You to heavyiron For This Useful Post:
basskiller  (09-29-2010)
Advertisements
Advertise at WCBB
Advertise at WCBB WCBB Is online now
Points: 413,418, Level: 100 Points: 413,418, Level: 100 Points: 413,418, Level: 100
Activity: 100% Activity: 100% Activity: 100%
 
Join Date: Jan 2004
Location: Looking for supplement deals
Posts: 60,683
Thanks: 11,143
Thanked 23,653 Times in 12,344 Posts
WCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond reputeWCBB has a reputation beyond repute

MuscleEgg Liquid Egg Whites
  #10  
Old 09-29-2010, 03:45 PM
heavyiron's Avatar
Community Veteran
 
Join Date: Sep 2010
Location: staying anabolic
Posts: 30
Thanks: 1
Thanked 13 Times in 11 Posts
Rep Power: 47
heavyiron is on a distinguished road
Pramipexole in treatment-resistant depression: a 16-week naturalistic study.

Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB.
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, University of Pisa, Italy. paolo.cassano@psico.med.unipi.it

OBJECTIVE: To assess the antidepressant efficacy and tolerability of adjunctive pramipexole, a D2-D3 dopamine agonist, in patients with drug-resistant depression. METHODS: The study sample consisted of in-patients with major depressive episode, according to the DSM-IV, and drug resistance. Pramipexole was added to antidepressant treatment with TCA or SSRI, at increasing doses from 0.375 to 1.0 mg/day. Two independent response criteria were adopted: a > 50% reduction of the Montgomery-Asberg Depressive Rating Scale (MADRS) total score and a score of I or 2 on the Clinical Global Impression scale (CGI-1) at endpoint. Side-effects were assessed by the Dosage Record Treatment Emergent Symptom Scale (DOTES). RESULTS: Thirty-seven patients were enrolled. Of these. 16 had unipolar depression and 21 had bipolar depression. Six patients dropped out in the first week. Of the 31 patients included in the analyses. 19 completed the 16-week follow-up. Mean maximal dose of pramipexole was 0.95 mg/day. Mean scores on MADRS decreased from 33.3 +/- 8.4 at baseline to 13.9 +/- 11.5 at endpoint (p < 0.001) and the CGI-S decreased from 4.6 +/- 0.8 at baseline to 2.8 +/- 1.3 at endpoint (p < 0.001). At endpoint, 67.7% (21/31) of patients were responders on MADRS and 74.2% on CGI-I. Of the 37 patients enrolled, 10 discontinued pramipexole because of adverse events. CONCLUSIONS: These preliminary data suggest that pramipexole adjunction to antidepressant treatment may be effective and well tolerated in patients with resistant major depression.
PMID: 12479663 [PubMed - indexed for MEDLINE]
Reply With Quote
The Following User Says Thank You to heavyiron For This Useful Post:
basskiller  (09-29-2010)
Reply

Bookmarks



Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools
Display Modes



All times are GMT -6. The time now is 02:32 AM.



Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.
Content Relevant URLs by vBSEO 3.6.0 PL2
Bodybuilding Peptide Use eXTReMe Tracker

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174